Research Topic

Exploring the Breast Tumor Microenvironment: Association to Metastasis, Novel Risk Factors and Novel Treatments and Immunotherapies

About this Research Topic

This Research Topic is dedicated to collating the latest information of biological factors associated to tumor microenvironment, and anti-cancer mediated. The role of the immune system in the eradication of cancers has been investigated for several decades with controversial findings. Researchers investigating the tumor microenvironment have uncovered a number of pathways that up- or downregulate immune cell activity. Research into those pathways has already led to a new class of immuno-oncology treatments known as checkpoint inhibitors, which disrupt immunosuppression and restore T cell activity. The controversy was the result of a poor understanding of the underlying mechanisms that govern responsiveness and unresponsiveness. Hence, significant advances have been made with respect to the regulation of the host immune response against cancer and several immuno-therapeutics have been recently introduced and used clinically. Various studies have examined potential underlying mechanisms involved in resistance and identified a variety of gene products that play pivotal roles in maintaining the resistant phenotype of the cancer cells to cell-mediated immunotherapy. Emphasis is on the biochemical, molecular, and genetic mechanisms by which the tumor spreads and resist.

The scope of this Research Topic will be to provide updated information to scientists and clinicians that is valuable in their quest to gather information, carry out new investigations, and develop novel immuno-sensitizing agents that are both more potent and also that might be active whereby the existing ones were not active.

This Research Topic aims:

- To provide basic and clinical evidence based on molecular interactions and clinical studies to address the tumor microenvironment, its role on metastasis, novel risk factors and risk and benefits of novel cancer immunotherapy.
- To present the results of new immunotherapy trials, discussing the state-of-the-art in breast cancer, including targeted therapies approved by the FDA, along with therapies with clinical potential used in basic studies


Keywords: Breast cancer, Metastasis, Tumor Microenvironment, Risk factors, immune check points, novel therapies


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

This Research Topic is dedicated to collating the latest information of biological factors associated to tumor microenvironment, and anti-cancer mediated. The role of the immune system in the eradication of cancers has been investigated for several decades with controversial findings. Researchers investigating the tumor microenvironment have uncovered a number of pathways that up- or downregulate immune cell activity. Research into those pathways has already led to a new class of immuno-oncology treatments known as checkpoint inhibitors, which disrupt immunosuppression and restore T cell activity. The controversy was the result of a poor understanding of the underlying mechanisms that govern responsiveness and unresponsiveness. Hence, significant advances have been made with respect to the regulation of the host immune response against cancer and several immuno-therapeutics have been recently introduced and used clinically. Various studies have examined potential underlying mechanisms involved in resistance and identified a variety of gene products that play pivotal roles in maintaining the resistant phenotype of the cancer cells to cell-mediated immunotherapy. Emphasis is on the biochemical, molecular, and genetic mechanisms by which the tumor spreads and resist.

The scope of this Research Topic will be to provide updated information to scientists and clinicians that is valuable in their quest to gather information, carry out new investigations, and develop novel immuno-sensitizing agents that are both more potent and also that might be active whereby the existing ones were not active.

This Research Topic aims:

- To provide basic and clinical evidence based on molecular interactions and clinical studies to address the tumor microenvironment, its role on metastasis, novel risk factors and risk and benefits of novel cancer immunotherapy.
- To present the results of new immunotherapy trials, discussing the state-of-the-art in breast cancer, including targeted therapies approved by the FDA, along with therapies with clinical potential used in basic studies


Keywords: Breast cancer, Metastasis, Tumor Microenvironment, Risk factors, immune check points, novel therapies


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

03 August 2021 Abstract
01 December 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

03 August 2021 Abstract
01 December 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..